RT Journal Article
SR Electronic
T1 Sensitive detection of copy number alterations in samples with low circulating tumor DNA fraction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.04.24306860
DO 10.1101/2024.05.04.24306860
A1 Mayrhofer, Markus
A1 Bergström, Rebecka
A1 Chellappa, Venkatesh
A1 Kotsalaynen, Anastassija
A1 Murugan, Sarath
A1 Crippa, Alessio
A1 De Laere, Bram
A1 Urtishak, Karen
A1 Sorensen, Karina Dalsgaard
A1 Garg, Kavita
A1 Singh, Usha
A1 Eklund, Martin
A1 Grönberg, Henrik
A1 Lindberg, Johan
YR 2024
UL http://medrxiv.org/content/early/2024/05/06/2024.05.04.24306860.abstract
AB Copy number analysis is an important aspect of cancer genomics that enables identification of activated oncogenes, inactivated tumor suppressor genes and genome-wide signatures such as homologous recombination deficiency and the tandem duplication phenotype. Despite continuous development of copy number algorithms, the current sensitivity to detect clinically relevant focal alterations is poor if the cancer DNA fraction is low. This is particularly challenging for analysis of circulating tumor DNA (ctDNA) as it is not possible to know the cancer DNA fraction in advance or, as for tissue, macrodissect to increase the cancer DNA fraction. Here, we combine a novel algorithm (Jumble) with a tailored gene panel design and selected reference samples that achieve sensitive and highly specific detection of clinically relevant copy number alterations with limits of detection at 1-2% ctDNA fraction for amplifications and 4-8% for homozygous deletions. Jumble lowers the ctDNA fraction required for detection of homozygous deletions 3-6 times compared to commercial alternatives. Jumble is freely available as an R script and container, ready for integration into bioinformatic pipelines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSwedish Cancer Society, Swedish Research Council, Swedish prostate cancer foundation, Radiumhemmets reserach foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Swedish Ethical Review Authority (Sweden) gave ethical approval for this work. The National Committee on Health Research Ethics (Denmark) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data relevant for the interpretation of our findings is provided in the main manuscript or the supplemental information. Dataset 1: Panel sequencing data, cfDNA and matched gDNA, from the ProBio trial (ClinicalTrials.gov identifier: NCT03903835, www.probiotrial.org). Any data providing information on individual outcomes or genotypes is considered to be a personal registry by the Swedish law (Personal Data Act), thereby prohibiting the submission of the sequencing files to a public repository. Access to the sequencing data data requires approval from the Swedish Ethical Review Authority and an agreement with the data protection- and legal unit at Karolinska Institutet. Dataset 2: Panel sequencing data of cfDNA from the MAGNITUDE trial (ClinicalTrials.gov identifier: NCT03748641). The data sharing policy is described in the publication, "Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer", pmid 36952634. Dataset 3: Panel sequencing data and low-pass whole genome sequencing from a Danish retrospective cohort. See publication "Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer", pmid 36762756, for data access information.